$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Topical medicament preparations 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-031/71
  • A61K-031/13
출원번호 US-0422891 (1982-09-24)
발명자 / 주소
  • Johnson Dee L. (Woodbury MN) Senta Therese A. (Minneapolis MN) Sirvio Larry M. (Cottage Grove MN)
출원인 / 주소
  • Minnesota Mining and Manufacturing Company (St. Paul MN 02)
인용정보 피인용 횟수 : 46  인용 특허 : 0

초록

Topical therapeutic compositions are disclosed which contain from about 0.1 to 70 percent by weight of a water-soluble tertiary amine oxide and a therapeutic agent selected from the group consisting of erythromycin, benzoyl peroxide, hydrocortisone, tetracycline, 5-fluorouracil, and propranolol. The

대표청구항

A composition for topical application to animal skin comprising: (1) an effective amount of a therapeutic agent selected from the group consisting of erythromycin, benzoyl peroxide, hydrocortisone, tetracycline, 5-fluorouracil, and propranolol; (2) about 0.1 to 70 percent by weight of a water-solubl

이 특허를 인용한 특허 (46)

  1. Ciufolini, Marco; Wermuth, Camille; Giethlen, Bruno; Moussy, Alain, 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors.
  2. Ciufolini, Marco; Wermuth, Camille; Giethlen, Bruno; Moussy, Alain, 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors.
  3. Ciufolini, Marco; Wermuth, Camille; Giethlen, Bruno; Moussy, Alain; Kinet, Jean-Pierre, 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors.
  4. Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno, 2-aminoaryloxazole compounds as tyrosine kinase inhibitors.
  5. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James Hurn-Joung; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod.
  6. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James H.; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod.
  7. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James H.; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod.
  8. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James H.; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod.
  9. Vogel Emanuel (Cologne DEX) Mueller Martin (Cologne DEX) Halpern Otto (Gerona ESX) Cross Alexander D. (Atherton CA), 9-Substituted porphycenes.
  10. Chakrabarti Paritosh M. (Pittsburgh PA) Denison John M. (Westmount OH CAX) Johnson Harlan B. (Rittman OH) Korach Malcolm (Akron OH) Leatherman Dennis D. (Pittsburgh PA) Reinhardt Linda P. (Lake Charl, Active agent delivery device.
  11. Chakrabarti, Paritosh M.; Johnson, Harlan B.; Korach, Malcolm; Leatherman, Dennis D.; Simmons, Robert R., Active agent delivery device.
  12. Bouillon Claude (Eaubonne FRX) Lang Gerard (Epinay Sur Seine FRX) Laugier Jean-Pierre (Antony FRX), Antiacne composition containing benzoic peroxide in association with at least one sun filter.
  13. Benjahad, Abdellah; Martin, Jason; Schalon, Claire; Pez, Didier; Chevenier, Emmanuel; Sandrinelli, Franck; Picoul, Willy; Moussy, Alain, Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors.
  14. Yu, Chongxi, High penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds.
  15. Yu, Chongxi, High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof.
  16. Stoesz, James D.; Statham, Alexis S.; Truong, Myhanh T., Immune response modifier compositions and methods.
  17. Statham, Alexis S.; Nelson, Robert J., Immune response modifier formulations containing oleic acid and methods.
  18. Statham, Alexis S.; Nelson, Robert J., Immune response modifier formulations containing oleic acid and methods.
  19. Shroot, Braham; Seal, Lawton A.; Hunt, James R.; Sterling, Jonathan; Bolsen, Kathy; Sitka, Penny L., Low temperature disinfectant/sterilant for medical devices and topical applications.
  20. Nordsiek, Michael T.; Gregory, Jefferson J., Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts.
  21. Nordsiek, Michael T.; Gregory, Jefferson J., Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts.
  22. Nordsiek, Michael T.; Gregory, Jefferson J., Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts.
  23. Nordsiek, Michael T.; Gregory, Jefferson J., Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts.
  24. Sefton John, Method and composition for treating acne.
  25. Saito Kenichiro (Menlo Park CA) Heller Jorge (Woodside CA) Skinner Wilfred A. (Portla Valley CA), Method for percutaneously administering metoclopramide.
  26. Burckhalter Joseph H. (2201 Melrose Ann Arbor MI 48104), Method of inhibiting herpetic lesions.
  27. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James H.; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, Method of treating actinic keratosis with 3.75% imiquimod cream.
  28. Nordsiek, Michael T.; Levy, Sharon F.; Lee, James H.; Kulp, James H.; Balaji, Kodumudi S.; Meng, Tze-Chiang; Wu, Jason J.; Bahm, Valyn S.; Babilon, Robert, Method of treating actinic keratosis with 3.75% imiquimod cream.
  29. Gregory, Jefferson J.; Nordsiek, Michael T., Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy.
  30. Gregory, Jefferson J.; Nordsiek, Michael T., Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy.
  31. Statham, Alexis S.; Henderson, Julie M.; Lundquist, Kevin G., Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation.
  32. Hardy Robert E. (106 River Run Greenwich CT 06830), Personal lubricant.
  33. Voet, Martin A., Photodynamic therapy for pre-melanomas.
  34. Grierson, David; Benjahad, Abdellah; Moussy, Alain; Croisy, Martine, Substituted oxazole derivatives and their use as tyrosine kinase inhibitors.
  35. De Villez Richard L. (San Antonio TX), Therapeutic compositions containing benzoyl peroxide.
  36. Moussy, Alain; Benjahad, Abdellah; Martin, Jason; Chevenier, Emmanuel; Pez, Didier; Sandrinelli, Franck; Picoul, Willy, Thiazole and oxazole kinase inhibitors.
  37. Sloan Kenneth B. (3551 NW. 23 Pl. Gainesville FL 32605) Beall Howard D. (4507 SW. 83rd Dr. Gainesville FL 32608), Topical 5-fluorouracil prodrug composition and method.
  38. Wick Steven M. ; Schultz Helen Jensen ; Nelson Gregory R. ; Mitra Amit K. ; Berge Stephen M., Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-C]quinolin-4-amine.
  39. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  40. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  41. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  42. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  43. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  44. Chang, Yunik; Dow, Gordon J., Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  45. Chang, Yunik; Dow, Gordon J.; Pillai, Radhakrishnan, Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
  46. Chang, Yunik; Dow, Gordon J.; Pillai, Radhakrishnan, Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로